The role of financial distress as a patient-relevant endpoint in early benefit assessments for oncology drugs: a mixed-methods document analysis

Key Points

• This research aims to explore the significance of financial distress as a relevant endpoint in evaluating oncology drugs from the patient's perspective.
• Conducted a mixed-methods document analysis of existing guidelines and assessments.
• Evaluated the role of financial distress in patient-reported outcomes.
• Identified gaps and suggested improvements in current methodologies.
• Emphasizes the need for clearer guidelines on integrating psychosocial factors.
• Found that current assessments often overlook financial distress as a patient-relevant outcome.
• Proposes refined measurement strategies to capture the complexity of financial distress.